```html

Fahr’s Disease – Comprehensive Medical Guide

Overview

Fahr’s disease, also known as primary familial brain calcification (PFBC), is a rare, progressive neurological disorder characterized by abnormal calcium deposits in specific areas of the brain, most commonly the basal ganglia, thalamus, cerebellum, and cerebral cortex. These deposits can interfere with normal neuronal signaling, leading to a wide spectrum of neurological and psychiatric manifestations.

Although the condition can appear at any age, it most frequently presents in the third to fifth decade of life. Both males and females are affected, and a hereditary pattern is seen in roughly 50 % of cases, often following an autosomal‑dominant inheritance. The overall prevalence is estimated at 0.5–2 per 100,000 individuals worldwide, but because many individuals remain asymptomatic, the true frequency is likely higher.<sup>[1] Mayo Clinic; [2] NIH Genetic and Rare Diseases Information Center</sup>

Symptoms

The clinical picture of Fahr’s disease is highly variable; some patients remain symptom‑free while others develop severe disability. Common symptoms can be grouped by system:

Neurologic Symptoms

• Movement disorders – Parkinsonism (tremor, rigidity, bradykinesia), chorea, dystonia, and ataxia are reported in 30‑60 % of patients.
• Seizures – Focal or generalized seizures occur in roughly 25 % of cases.
• Gait disturbances – Unsteady or shuffling gait, frequent falls.
• Headache – Often dull and persistent, sometimes misattributed to tension.
• Speech problems – Dysarthria or slowed speech.

Cognitive & Psychiatric Symptoms

• Cognitive decline – Memory loss, slowed processing, executive dysfunction.
• Mood disorders – Depression, anxiety, irritability.
• Psychosis – Hallucinations or delusional thinking in up to 15 % of patients.
• Personality changes – Apathy, disinhibition, or emotional lability.

Other Manifestations

• Vertigo & dizziness – Frequently reported before motor signs appear.
• Peripheral neuropathy – Numbness or tingling in extremities (rare).
• Vision disturbances – Blurred vision or nystagmus when the cerebellum is involved.

Because symptoms progress slowly over years, many individuals first seek care for a single complaint (e.g., tremor or mood changes) before the full syndrome is recognised.

Causes and Risk Factors

Fahr’s disease can be divided into two broad categories:

Genetic (Primary) Forms

• Autosomal‑dominant genes – Mutations in SLC20A2, PDGFB, PDGFRB, and XPR1 account for ~70 % of familial cases.<sup>[3] Cleveland Clinic</sup>
• Autosomal‑recessive genes – Rare mutations in MYORG and CMPK2 have been described.
• These genes affect phosphate transport or blood‑brain barrier integrity, leading to calcium‑phosphate precipitation.

Secondary (Acquired) Causes

• Metabolic disorders – Hypoparathyroidism, pseudohypoparathyroidism, hyperparathyroidism.
• Infections – TORCH infections, HIV, or chronic fungal disease.
• Toxic exposures – Lead, aluminum, or chronic alcohol.
• Other neurological conditions – Multiple sclerosis or mitochondrial disease.

Risk Factors

• Family history of brain calcifications.
• Known mutations in the genes listed above.
• Chronic electrolyte disturbances, especially low calcium or abnormal phosphate.
• Age >30 years (most symptomatic presentations).

Diagnosis

Diagnosing Fahr’s disease relies on a combination of clinical evaluation, imaging, and exclusion of secondary causes.

Step‑by‑Step Diagnostic Approach

1. Detailed history & neurological exam – Focus on movement, cognition, and psychiatric symptoms.
2. Blood tests – Calcium, phosphate, magnesium, parathyroid hormone (PTH), vitamin D, renal and liver panels to rule out metabolic causes.
3. Neuroimaging – The cornerstone of diagnosis.
   • CT scan – Shows symmetric, bilateral calcifications in basal ganglia, thalami, dentate nuclei, and subcortical white matter. Sensitivity >90 %.
   • MRI – Helpful for assessing associated white‑matter changes or ruling out other lesions; calcifications appear as low signal on T2‑weighted images.
4. Genetic testing – Targeted panel or whole‑exome sequencing for known PFBC genes, especially when a family history is present.
5. Exclusion of secondary etiologies – Negative work‑up for parathyroid disease, infections, toxic exposures, or other metabolic abnormalities confirms a primary diagnosis.

Professional societies recommend that a diagnosis of “primary Fahr’s disease” be made only after secondary causes have been excluded and imaging criteria are met.<sup>[4] WHO Guidelines on Rare Neurological Disorders</sup>

Treatment Options

There is currently no cure that reverses brain calcifications. Management focuses on symptom control, preventing complications, and addressing any underlying metabolic disturbance.

Medication

• Movement disorders
  • Levodopa/Carbidopa – Helpful for Parkinsonian features in ~30 % of patients.
  • Anticholinergics (e.g., trihexyphenidyl) – May reduce tremor but carry cognitive side‑effects.
  • Baclofen or tizanidine – For dystonia.
• Seizure control
  • First‑line agents: levetiracetam, lamotrigine, or valproic acid.
  • Avoid drugs that lower seizure threshold (e.g., bupropion).
• Psychiatric symptoms
  • SSRIs for depression/anxiety.
  • Atypical antipsychotics (e.g., quetiapine) for psychosis – use cautiously due to potential extrapyramidal side‑effects.
• Metabolic correction (if secondary cause identified)
  • Calcium and active vitamin D supplementation for hypoparathyroidism.
  • Phosphate binders or dietary phosphate restriction when hyperphosphatemia is present.

Procedural & Surgical Options

• Deep Brain Stimulation (DBS) – Small case series suggest benefit for refractory Parkinsonism or dystonia, but evidence is limited.
• Seizure surgery – Considered only when seizures are focal and medication‑resistant.

Lifestyle & Supportive Measures

• Regular aerobic exercise to preserve mobility and mood.
• Physical therapy for gait stability and balance.
• Occupational therapy for fine‑motor tasks and activities of daily living (ADLs).
• Speech therapy when dysarthria is present.
• Neuropsychological evaluation and cognitive rehabilitation.
• Support groups and counselling for patients and caregivers.

Living with Fahr’s Disease

Because the condition progresses at an individual rate, a personalized management plan is essential.

Daily Management Tips

• Medication adherence – Use pillboxes or smartphone reminders.
• Fall prevention – Install grab bars, keep walkways clear, wear supportive shoes.
• Routine monitoring – Schedule neurology follow‑up every 6‑12 months and repeat blood work if a metabolic abnormality was previously identified.
• Nutrition – Maintain a balanced diet rich in calcium and vitamin D, unless they exacerbate hyperphosphatemia.
• Stress management – Mindfulness, yoga, or gentle stretching can reduce anxiety and improve sleep.
• Driving assessment – Obtain formal evaluation if gait or cognition declines.
• Advance care planning – Discuss goals of care early, especially if cognitive decline becomes significant.

Support Resources

National rare‑disease organisations, such as the National Organization for Rare Disorders (NORD), provide patient registries, educational material, and connections to specialists experienced in PFBC.

Prevention

Because primary Fahr’s disease is genetic, primary prevention is not possible for those who carry pathogenic variants. However, secondary forms can often be prevented or mitigated:

• Maintain normal calcium‑phosphate balance – regular monitoring for patients with hypoparathyroidism or chronic kidney disease.
• Avoid long‑term exposure to neurotoxic metals (lead, aluminum) and excessive alcohol.
• Prompt treatment of infections that can affect the brain (e.g., viral encephalitis).
• Genetic counselling for families with a known mutation to inform reproductive choices.

Complications

If left untreated or poorly managed, Fahr’s disease can lead to several serious complications:

• Progressive motor disability – Increased dependence for ADLs, risk of fractures from falls.
• Refractory epilepsy – May require intensive monitoring or surgical intervention.
• Dementia – Severe cognitive decline affecting decision‑making capacity.
• Psychiatric crises – Acute psychosis or severe depression with suicidal ideation.
• Secondary complications – Pressure ulcers, urinary tract infections, or aspiration pneumonia due to reduced mobility.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Fahr disease.” Updated 2023. https://www.mayoclinic.org
2. Genetic and Rare Diseases Information Center (GARD), National Institutes of Health. “Primary Familial Brain Calcification.” 2022.
3. Cleveland Clinic. “Genetics of Primary Familial Brain Calcification.” 2021. https://my.clevelandclinic.org
4. World Health Organization. “Guidelines for the Diagnosis and Management of Rare Neurological Disorders.” 2020.
5. National Organization for Rare Disorders (NORD). “Fahr Disease.” 2023.

```